These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21049059)

  • 1. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A; Musa A; Wasunna M; Balasegaram M; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tesfaye S; Makonnen E; Khalil E; Ahmed O; Fadlalla A; El-Hassan A; Raheem M; Mueller M; Koummuki Y; Rashid J; Mbui J; Mucee G; Njoroge S; Manduku V; Musibi A; Mutuma G; Kirui F; Lodenyo H; Mutea D; Kirigi G; Edwards T; Smith P; Muthami L; Royce C; Ellis S; Alobo M; Omollo R; Kesusu J; Owiti R; Kinuthia J;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):e709. PubMed ID: 21049059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
    PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.
    Musa AM; Younis B; Fadlalla A; Royce C; Balasegaram M; Wasunna M; Hailu A; Edwards T; Omollo R; Mudawi M; Kokwaro G; El-Hassan A; Khalil E
    PLoS Negl Trop Dis; 2010 Oct; 4(10):e855. PubMed ID: 21049063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM; Mbui J; Mohammed R; Olobo J; Ritmeijer K; Alcoba G; Muthoni Ouattara G; Egondi T; Nakanwagi P; Omollo T; Wasunna M; Verrest L; Dorlo TPC; Musa Younis B; Nour A; Taha Ahmed Elmukashfi E; Ismail Omer Haroun A; Khalil EAG; Njenga S; Fikre H; Mekonnen T; Mersha D; Sisay K; Sagaki P; Alvar J; Solomos A; Alves F
    Clin Infect Dis; 2023 Feb; 76(3):e1177-e1185. PubMed ID: 36164254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
    Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.
    van Dijk N; Carter J; Kiptanui D; Pinelli E; Schallig H
    Parasitology; 2024 Jun; 151(7):753-761. PubMed ID: 39311405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
    Khalil EA; Weldegebreal T; Younis BM; Omollo R; Musa AM; Hailu W; Abuzaid AA; Dorlo TP; Hurissa Z; Yifru S; Haleke W; Smith PG; Ellis S; Balasegaram M; EL-Hassan AM; Schoone GJ; Wasunna M; Kimutai R; Edwards T; Hailu A
    PLoS Negl Trop Dis; 2014; 8(1):e2613. PubMed ID: 24454970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
    Omollo R; Alexander N; Edwards T; Khalil EA; Younis BM; Abuzaid AA; Wasunna M; Njoroge N; Kinoti D; Kirigi G; Dorlo TP; Ellis S; Balasegaram M; Musa AM
    Trials; 2011 Jun; 12():166. PubMed ID: 21718522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
    Thakur CP; Kanyok TP; Pandey AK; Sinha GP; Zaniewski AE; Houlihan HH; Olliaro P
    Trans R Soc Trop Med Hyg; 2000; 94(4):429-31. PubMed ID: 11127250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.